Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research (JAMPBR)

Incidence of Pulmonary Hypertension in Obese Patients with COVID-19 in Intensive Care Units

Document Type : Original Article

Authors

Mir Mohammad Taghi Mortazavi 1
Mansour Rezaei 1
Mozhdeh Nikfar 2

1 Associate Professor of Anesthesiology, Department of Anesthesiology, School of Medicine, Tabriz, Iran

2 Assistant Professor of Pulmonary Diseases, Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

10.5281/zenodo.22735930
Abstract
Introduction: COVID-19 often triggers acute pulmonary hypertension, a life-threatening vascular complication whose risk is markedly amplified by obesity in critically ill patients. However, the precise incidence of this hemodynamic condition within intensive care settings remains inadequately quantified. Therefore, this study aimed to determine the incidence of pulmonary hypertension in obese COVID-19 patients admitted to intensive care units.

Material and methods: This descriptive cross-sectional study was conducted at Imam Reza Hospital. Using convenience sampling and the Cochran formula, a sample of 71 obese COVID-19 patients was recruited. The procedure involved comprehensive assessment of hemodynamic parameters, including pulmonary artery pressures, oxygen saturation, and anthropometric data, to evaluate the incidence of pulmonary hypertension in the intensive care setting.

Results: In critically ill COVID-19 patients, pulmonary hypertension (PH) was associated with higher BMI (36.5±3.4 vs. 32.8±2.9 kg/m²; p=0.002), elevated APACHE II scores (18.6±4.1 vs. 14.8±3.5; p=0.001), longer ICU stay (14.1±5.6 vs. 11.2±4.2 days; p=0.015), and severe impairment in PASP (48.6±7.5 mmHg; p<0.001), mPAP (32.4±5.6 mmHg; p<0.001), PaO2/FiO2 (165.2±38.6; p=0.004), D-dimer (2800 ng/mL; p=0.001), and CRP (72.8±18.5 mg/L; p=0.003). Class III obesity independently portended the greatest risk (OR=7.95; p<0.001).

Conclusion: Severe obesity independently drives acute pulmonary vascular complications in critically ill COVID-19 patients, significantly worsening hemodynamics, oxygenation, systemic inflammation, and clinical outcomes. Escalating adiposity classes exhibit a clear dose-dependent risk of pulmonary hypertension. Early hemodynamic evaluation and targeted vascular therapies are imperative in obese ICU patients with COVID-19 to mitigate microvascular injury and improve survival.

Graphical Abstract

Incidence of Pulmonary Hypertension in Obese Patients with COVID-19 in Intensive Care Units

Keywords

Obesity
Pulmonary Hypertension
COVID-19
Intensive Care Units
Subjects
[1]    Hosseini, E. S., Kashani, N. R., Nikzad, H., Azadbakht, J., Bafrani, H. H., & Kashani, H. H. (2020). The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology, 551, 1–9.
[2]    Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., … Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727–733.
[3]    Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., … Pillai, S. K. (2020). First case of 2019 novel coronavirus in the United States. New England Journal of Medicine, 382(10), 929–936.
[4]    Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. Acta Bio-Medica, 91(1), 157–160.
[5]    Seyed Hoseini, S V and Nasseri, A R. (2026). Identification of Predictive Factors for Late Radiotherapy Induced Complications in Post Mastectomy Breast Cancer Survivors. Medicinal, Psychological, and Health Research Journal (MPHRJ), 2(6), 409-418.
[6]    Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615.
[7]    Dadhwal, R., Sharma, M., & Surani, S. (2021). Restrictive lung disease in patients with subclinical coronavirus infection: Are we bracing ourselves for devastating sequelae? Cureus, 13(1), e12501.
[8]    George, P. M., Wells, A. U., & Jenkins, R. G. (2020). Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. The Lancet Respiratory Medicine, 8(8), 807–815.
[9]    Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020). Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulmonary Medicine, 2020, 6175964.
[10] Ojha, V., Mani, A., Pandey, N. N., Sharma, S., & Kumar, S. (2020). CT in coronavirus disease 2019 (COVID-19): A systematic review of chest CT findings in 4410 adult patients. European Radiology, 30(11), 6129–6138.
[11] Polak, S. B., Van Gool, I. C., Cohen, D., von der Thüsen, J. H., & van Paassen, J. (2020). A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Modern Pathology, 33(11), 2128–2138.
[12] Lu, Z. H., Yang, C. L., Yang, G. G., Pan, H. X., Li, S., Wang, Y. X., … Wang, X. H. (2021). Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequela in convalescent COVID-19 patients: A randomized multicenter trial. Infectious Diseases of Poverty, 10(1), 31.
[13] Gao, Z., Xu, Y., Sun, C., Wang, X., Guo, Y., Qiu, S., & Ma, K. (2021). A systematic review of asymptomatic infections with COVID-19. Journal of Microbiology, Immunology and Infection, 54(1), 12–16.
[14] Wigén, J., Löfdahl, A., Bjermer, L., Elowsson-Rendin, L., & Westergren-Thorsson, G. (2020). Converging pathways in pulmonary fibrosis and Covid-19 — The fibrotic link to disease severity. Respiratory Medicine X, 2, 100023.
[15] McDonald, L. T. (2021). Healing after COVID-19: Are survivors at risk for pulmonary fibrosis? American Journal of Physiology — Lung Cellular and Molecular Physiology, 320(2), L257–L265.
[16] Vasarmidi, E., Tsitoura, E., Spandidos, D. A., Tzanakis, N., & Antoniou, K. M. (2020). Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Experimental and Therapeutic Medicine, 20(3), 2557–2560.
[17]  Seyed Hoseini, S V and Nasseri, A R. (2026). Clinical Significance of Preoperative Serum Albumin Levels in Predicting Survival After Surgery in Patients Undergoing Colorectal Cancer Resection. Medicinal, Psychological, and Health Research Journal (MPHRJ), 2(6), 419-428.
[18] Bharat, A., Machuca, T. N., Querrey, M., Kurihara, C., Garza-Castillon, R., Kim, S., … Cypel, M. (2021). Early outcomes after lung transplantation for severe COVID-19: A series of the first consecutive cases from four countries. The Lancet Respiratory Medicine, 9(5), 487–497.
[19] Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., … Sung, J. J. Y. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine, 348(20), 1986–1994.
[20] Lew, T. W. K., Kwek, T. K., Tai, D., Earnest, A., Loo, S., Singh, K., … Ang, B. (2003). Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA, 290(3), 374–380.
[21] Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., … Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720.
[22] Gentile, F., Aimo, A., Forfori, F., Catapano, G., Clemente, A., Cademartiri, F., … Emdin, M. (2020). COVID-19 and risk of pulmonary fibrosis: The importance of planning ahead. European Journal of Preventive Cardiology, 27(13), 1442–1446.
[23] Barison, A., Aimo, A., Castiglione, V., Arzilli, C., Lupón, J., Ghadri, J. R., … Emdin, M. (2020). Cardiovascular disease and COVID-19: Les liaisons dangereuses. European Journal of Preventive Cardiology, 27(10), 1017–1025.
[24] Isidori, A. M., Giannetta, E., Pofi, R., Venneri, M. A., Gianfrilli, D., Campolo, F., … Lenzi, A. (2021). Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection: The DEDALO project. Andrology, 9(1), 33–38.
[25] Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., … Ferguson, N. M. (2020). Estimates of the severity of coronavirus disease 2019: A model-based analysis. The Lancet Infectious Diseases, 20(6), 669–677.
[26] Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., … Song, Y. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine, 180(7), 934–943.
[27] Abdel-Hamid, H. M., Rizk, H. I., & Magdy, S. (2021). Occurrence of pulmonary residuals as one of the sequelae of COVID-19 and its predictors among moderate and severe cases. Indian Journal of Tuberculosis, 68(4), 450–456.
[28] Mossel, E. C., Wang, J., Jeffers, S., Edeen, K. E., Wang, R., Cosgrove, G. P., … Mason, R. J. (2008). SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology, 372(1), 127–135.
[29] Weinheimer, V. K., Becher, A., Tönnies, M., Holland, G., Knepper, J., Bauer, T. T., … Schaudien, D. (2012). Influenza A viruses target type II pneumocytes in the human lung. The Journal of Infectious Diseases, 206(11), 1685–1694.
[30] Mason, R. J. (2020). Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal, 55(4), 2000607.
[31] Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., … Hu, Y. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care, 24(1), 422.
[32] Leng, L., Cao, R., Ma, J., Mou, D., Zhu, Y., Li, W., … Zhong, W. (2020). Pathological features of COVID-19-associated lung injury: A preliminary proteomics report based on clinical samples. Signal Transduction and Targeted Therapy, 5(1), 240.
[33] Kobayashi, T., Tanaka, K., Fujita, T., Umezawa, H., Amano, H., Yoshioka, K., … Matsutani, T. (2015). Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respiratory Research, 16(1), 99.
[34] Lee, J. S., Lee, E. Y., Ha, Y. J., Kang, E. H., Lee, Y. J., & Song, Y. W. (2019). Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Research & Therapy, 21(1), 58.
[35] Selman, M., King, T. E., & Pardo, A. (2001). Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of Internal Medicine, 134(2), 136–151.
[36] Zou, J. N., Sun, L., Wang, B. R., Wang, Y., Yang, J., Wang, X. J., … Wang, Y. (2021). The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLOS ONE, 16(3), e0248957.
[37] Guiot, J., Moermans, C., Henket, M., Corhay, J. L., & Louis, R. (2017). Blood biomarkers in idiopathic pulmonary fibrosis. Lung, 195(3), 273–280.
[38] Vij, R., & Noth, I. (2012). Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Translational Research, 159(4), 218–227.
[39] Peng, D. H., Luo, Y., Huang, L. J., Liao, X. L., Liu, Y. S., Tang, P., … Liu, Z. H. (2021). Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019. Clinica Chimica Acta, 517, 48–53.
[40] Ko, U. W., Cho, E. J., Oh, H. B., Koo, H. J., Do, K. H., & Song, J. W. (2020). Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease. PLOS ONE, 15(12), e0244114.
[41] Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Masuda, T., Miyamoto, S., … Kohno, N. (2016). Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Disease Markers, 2016, 4759040.
[42] Awano, N., Inomata, M., Kuse, N., Tone, M., Takada, K., Muto, Y., … Izumo, T. (2020). Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019. Respiratory Investigation, 58(6), 440–447.
[43] d''Alessandro, M., Bergantino, L., Cameli, P., Cavallaro, D., De Simone, C., Marrucci, S., … Frediani, B. (2021). Serial KL-6 measurements in COVID-19 patients. Internal and Emergency Medicine, 16(6), 1541–1545.
[44] Vázquez de Lara, L., Becerril, C., Montaño, M., Ramos, C., Maldonado, V., Meléndez, J., … Pardo, A. (2000). Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. American Journal of Physiology — Lung Cellular and Molecular Physiology, 279(5), L950–L957.
Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research (JAMPBR)
Volume 2, Issue 6
November and December 2026
Pages 593-599

Home

Editorial Board

Guide for Authors

Submit Manuscript

Reviewers

Contact Us